Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a
wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug …

Efforts to develop new antiviral chemotherapeutic approaches are focusing on compounds
that target either influenza virus replication itself or host factor (s) that are critical to influenza …

Antifibrinolytic drugs are widely used to reduce blood loss during surgery. One serious
adverse effect of these drugs is convulsive seizures; however, the mechanisms underlying …

BACKGROUND: Aprotinin is superior to other antifibrinolytic drugs for preventing major
blood loss after cardiac surgery but may also increase perioperative mortality. It remains …

Myocardial infarction (MI) causes significant cell loss and damage to myocardium. Cell-
based therapies for treatment of MI aim to remuscularize the resultant scar tissue, but the …

The concept of patient blood management (PBM) was introduced by the World Health
Organization in 2011 and is defined as a “patient-focused, evidence-based and systematic …

The efficacy of the serine protease inhibitor, aprotinin, and the lysine analogs, ε-
aminocaproic acid and tranexamic acid, in reducing bleeding and transfusion in adults …

Background: Plasma kallikrein plays a major role in the contact (kallikrein–kinin) cascade
producing bradykinin. Bradykinin is a vasodilator, which increases vascular permeability …

OBJECTIVES: Anti-inflammatory effects of tranexamic acid and aprotinin, used to abate
perioperative blood loss, are reported and might be of substantial clinical relevance. The …

Antifibrinolytic drugs provide important pharmacological interventions to reduce morbidity
and mortality from excessive bleeding during surgery and after trauma. Current drugs used …